All News

Found 77 articles

• Eli Lilly Projects 20 New Product Launches in 10 Years with 20 Possible Expansions

  5/25/2016

• Eli Lilly Reports First-Quarter 2016 Results, Revises 2016 Financial Guidance

  4/26/2016

• Two Under-the-Radar Updates Pfizer Investors Need to Know About

  5/7/2015

• Pfizer Pockets $200 Million as Tanezumab Phase III Program With Eli Lilly Resumes

  3/23/2015

• Eli Lilly Provides Update On Strategy And Announces 2015 Financial Guidance

  1/7/2015

• Eli Lilly and Company Projects Spot-On '14 Profit Slump

  1/7/2014

• GlobalData Release: Osteoarthritis Pain Medications Struggle to Impress in Advanced Cases

  6/8/2012

• Tanezumab Helps OA, but Trials Stopped

  9/30/2010

• Tanezumab Helps Osteoarthritis, But Trials Stopped, University of California, Davis (UCD) Study

  9/30/2010

• Urigen Pharmaceuticals, Inc. Announces FDA Follow Up

  8/11/2010

• Pfizer Inc. Halts Tanezumab Studies For Back Pain, Diabetes

  7/21/2010

• Trial and Errors: Pfizer Inc.'s Drug Failures Are the Result of Bad Management, Not Clinical Misfortune

  6/25/2010

• Pfizer Inc. Halts Clinical Trials of Arthritis Drug, Tanezumab

  6/24/2010

• Pfizer Inc. (JOBS) Drops 100 Drugs from Pipeline

  1/29/2010

• Pfizer Inc. Drops Development of 2 Late-Stage Drugs

  2/24/2009

• XOMA (US) LLC Receives Milestone Payment From Pfizer Inc. Under Antibody Technology License

  1/22/2009

• Pfizer Inc. to Present Data on New Approaches to Pain and Inflammation Treatment at American College of Rheumatology Meeting

  10/27/2008